Trial Profile

A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms IZALCO
Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement

23 May 2024 Planned number of patients changed from 68 to 71.
23 May 2024 Planned End Date changed from 17 Feb 2027 to 1 Mar 2027.
23 May 2024 Planned primary completion date changed from 14 Oct 2024 to 24 Oct 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com